Index DJIA, S&P 500
P/E 21.50
EPS (ttm) 6.94
Insider Own 0.16%
Shs Outstand 2.41B
Perf Week 2.14%
Market Cap 359.71B
Forward P/E 13.62
EPS next Y 10.96
Insider Trans -1.74%
Shs Float 2.41B
Perf Month -2.12%
Income 17.49B
PEG 4.11
EPS next Q 2.71
Inst Own 71.36%
Short Float 0.69%
Perf Quarter -4.69%
Sales 89.66B
P/S 4.01
EPS this Y 7.40%
Inst Trans -0.39%
Short Ratio 2.13
Perf Half Y 0.39%
Book/sh 29.09
P/B 5.13
EPS next Y 2.88%
ROA 9.15%
Short Interest 16.56M
Perf Year -8.35%
Cash/sh 10.88
P/C 13.72
EPS next 5Y 5.23%
ROE 23.91%
52W Range 143.13 - 175.97
Perf YTD -4.77%
Dividend Est. 4.81 (3.22%)
P/FCF 19.23
EPS past 5Y -0.27%
ROI 18.39%
52W High -15.17%
Beta 0.53
Dividend TTM 4.76 (3.19%)
Quick Ratio 0.94
Sales past 5Y 1.31%
Gross Margin 68.49%
52W Low 4.29%
ATR (14) 2.63
Dividend Ex-Date May 20, 2024
Current Ratio 1.17
EPS Y/Y TTM 44.66%
Oper. Margin 25.66%
RSI (14) 47.81
Volatility 1.78% 1.59%
Employees 131900
Debt/Eq 0.48
Sales Y/Y TTM -6.90%
Profit Margin 19.51%
Recom 2.22
Target Price 172.96
Option/Short Yes / Yes
LT Debt/Eq 0.36
EPS Q/Q 5231.80%
Payout 84.93%
Rel Volume 0.82
Prev Close 149.92
Sales Surprise -0.08%
EPS Surprise 2.04%
Sales Q/Q -13.55%
Earnings Apr 16 BMO
Avg Volume 7.76M
Price 149.27
SMA20 0.66%
SMA50 -3.37%
SMA200 -5.51%
Trades
Volume 6,361,243
Change -0.43%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-18-24 Upgrade
HSBC Securities
Hold → Buy
$170
Dec-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$170 → $163
Dec-01-23 Upgrade
UBS
Neutral → Buy
$167 → $180
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$178
Sep-06-23 Initiated
HSBC Securities
Hold
$175
May-30-23 Resumed
Citigroup
Buy
$185
Mar-29-23 Initiated
UBS
Neutral
$164
Mar-01-23 Initiated
Guggenheim
Neutral
$161
Nov-18-22 Initiated
Credit Suisse
Neutral
$170
Oct-18-22 Initiated
Barclays
Equal Weight
$175
Oct-14-22 Reiterated
BofA Securities
Neutral
$185 → $178
Jun-22-22 Initiated
Daiwa Securities
Outperform
May-23-22 Resumed
SVB Leerink
Outperform
$200
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$173
Mar-16-22 Downgrade
Bernstein
Outperform → Mkt Perform
$180 → $183
Mar-02-22 Resumed
BofA Securities
Neutral
$185
Dec-17-21 Initiated
Goldman
Neutral
$161
Dec-15-21 Reiterated
Citigroup
Buy
$192 → $195
Sep-07-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$187
May-28-21 Resumed
Morgan Stanley
Overweight
$187
Show Previous Ratings
May-03-24 05:04PM
04:07PM
02:41PM
09:00AM
08:30AM
(Investor's Business Daily)
08:30AM
Loading…
08:30AM
05:00AM
May-02-24 12:20PM
06:51AM
(Pharmaceutical Technology)
03:01AM
(Pharmaceutical Technology)
01:04AM
May-01-24 04:26PM
04:11PM
04:00PM
03:57PM
03:48PM
Loading…
03:48PM
03:02PM
02:17PM
02:17PM
01:53PM
01:25PM
01:25PM
12:27PM
(The Wall Street Journal)
12:11PM
11:26AM
11:02AM
(Pharmaceutical Technology)
10:31AM
10:23AM
10:15AM
09:54AM
09:36AM
Loading…
09:36AM
09:35AM
09:33AM
09:03AM
08:46AM
07:20AM
07:15AM
(Associated Press Finance)
06:34AM
06:30AM
06:30AM
05:21AM
Apr-30-24 09:42AM
07:17AM
06:01AM
Apr-29-24 05:52PM
05:07PM
12:53PM
10:23AM
10:03AM
08:00AM
Apr-28-24 06:54PM
08:45AM
07:17AM
04:20AM
Apr-27-24 09:15AM
08:48AM
07:45AM
06:38AM
06:00AM
Apr-26-24 06:00AM
06:00AM
Apr-25-24 12:22PM
(Pharmaceutical Technology)
Apr-24-24 07:27AM
06:10AM
05:25AM
03:02AM
Apr-23-24 06:21PM
Apr-22-24 04:30PM
11:10AM
09:00AM
05:32AM
Apr-21-24 10:39AM
08:39AM
07:22AM
Apr-19-24 08:50PM
11:00AM
10:47AM
08:50AM
07:47AM
07:26AM
05:00AM
Apr-18-24 09:46PM
06:33PM
05:23PM
04:52PM
08:15AM
Apr-17-24 08:17AM
03:01AM
Apr-16-24 05:45PM
05:09PM
05:09PM
04:20PM
04:02PM
(Investor's Business Daily)
02:57PM
02:44PM
01:57PM
01:49PM
01:30PM
11:58AM
11:29AM
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
REED JOHN C EVP, Innovative Medicine, R&D May 01 '24 Option Exercise 0.00 22,255 0 22,561 May 03 04:31 PM Broadhurst Vanessa EVP, Global Corp Affairs Mar 13 '24 Sale 162.16 8,891 1,441,765 15,043 Mar 13 04:36 PM JOHNSON & JOHNSON 10% Owner Feb 29 '24 Option Exercise 0.72 3,855 2,792 4,103,430 Mar 06 03:42 PM JOHNSON & JOHNSON 10% Owner Feb 16 '24 Sale 25.81 3,725 96,142 4,099,575 Mar 06 03:42 PM Decker Robert J VP Corporate Controller Feb 13 '24 Option Exercise 0.00 313 0 19,059 Feb 15 04:53 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 13 '24 Option Exercise 0.00 408 0 24,143 Feb 15 04:53 PM Forminard Elizabeth Executive VP, General Counsel Feb 13 '24 Option Exercise 0.00 651 0 8,576 Feb 15 04:53 PM Duato Joaquin CEO and Chairman of the Board Feb 13 '24 Option Exercise 0.00 3,470 0 364,809 Feb 15 04:53 PM Hait William See Remarks Feb 13 '24 Option Exercise 0.00 834 0 39,074 Feb 15 04:53 PM Fasolo Peter Exec VP, Chief HR Officer Feb 13 '24 Option Exercise 0.00 925 0 112,550 Feb 15 04:53 PM Schmid Timothy EVP, WW Chair, MedTech Feb 13 '24 Option Exercise 0.00 499 0 13,290 Feb 15 04:53 PM Swanson James D. EVP, CIO Feb 13 '24 Option Exercise 0.00 447 0 14,765 Feb 15 04:53 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 13 '24 Option Exercise 0.00 1,302 0 155,517 Feb 15 04:53 PM Wolk Joseph J Exec VP, CFO Feb 13 '24 Option Exercise 0.00 1,780 0 69,663 Feb 15 04:53 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 13 '24 Option Exercise 0.00 651 0 82,599 Feb 15 04:53 PM Decker Robert J VP Corporate Controller Feb 12 '24 Option Exercise 0.00 1,912 0 19,269 Feb 14 06:36 PM Duato Joaquin CEO and Chairman of the Board Feb 12 '24 Option Exercise 0.00 36,618 0 377,239 Feb 14 06:36 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 12 '24 Option Exercise 0.00 26,202 0 167,618 Feb 14 06:36 PM Forminard Elizabeth Executive VP, General Counsel Feb 12 '24 Option Exercise 0.00 2,859 0 8,959 Feb 14 06:36 PM Wolk Joseph J Exec VP, CFO Feb 12 '24 Option Exercise 0.00 25,835 0 78,699 Feb 14 06:36 PM Hait William See Remarks Feb 12 '24 Option Exercise 0.00 8,932 0 42,316 Feb 14 06:36 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 12 '24 Option Exercise 0.00 4,701 0 25,081 Feb 14 06:36 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 12 '24 Option Exercise 0.00 13,813 0 89,014 Feb 14 06:36 PM Schmid Timothy EVP, WW Chair, MedTech Feb 12 '24 Option Exercise 0.00 5,736 0 15,678 Feb 14 06:36 PM Swanson James D. EVP, CIO Feb 12 '24 Option Exercise 0.00 5,456 0 16,013 Feb 14 06:36 PM Fasolo Peter Exec VP, Chief HR Officer Feb 12 '24 Option Exercise 0.00 14,960 0 118,644 Feb 14 06:36 PM Duato Joaquin CEO and Chairman of the Board Feb 09 '24 Option Exercise 90.44 130,969 11,844,836 439,283 Feb 13 05:18 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 09 '24 Option Exercise 90.44 59,397 5,371,865 200,813 Feb 12 07:25 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 09 '24 Sale 156.27 59,397 9,281,969 141,416 Feb 12 07:25 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 08 '24 Option Exercise 0.00 3,739 0 143,329 Feb 12 07:25 PM Decker Robert J VP Corporate Controller Feb 08 '24 Option Exercise 0.00 655 0 17,572 Feb 12 07:24 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 08 '24 Option Exercise 0.00 1,880 0 21,083 Feb 12 07:24 PM Hait William See Remarks Feb 08 '24 Option Exercise 0.00 3,059 0 34,497 Feb 12 07:24 PM Fasolo Peter Exec VP, Chief HR Officer Feb 08 '24 Option Exercise 0.00 2,135 0 104,465 Feb 12 07:24 PM Schmid Timothy EVP, WW Chair, MedTech Feb 08 '24 Option Exercise 0.00 1,964 0 10,943 Feb 12 07:24 PM Swanson James D. See Remarks Feb 08 '24 Option Exercise 0.00 1,868 0 11,111 Feb 12 07:24 PM Forminard Elizabeth Executive VP, General Counsel Feb 08 '24 Option Exercise 0.00 979 0 6,463 Feb 12 07:24 PM Wolk Joseph J Exec VP, CFO Feb 08 '24 Option Exercise 0.00 3,686 0 53,911 Feb 12 07:25 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 08 '24 Option Exercise 0.00 1,971 0 67,905 Feb 12 07:25 PM Duato Joaquin CEO and Chairman of the Board Feb 08 '24 Option Exercise 0.00 5,225 0 310,583 Feb 12 07:25 PM Hait William See Remarks Jul 26 '23 Option Exercise 90.44 14,698 1,329,287 102,445 Jul 27 05:52 PM Hait William See Remarks Jul 26 '23 Sale 172.00 14,698 2,528,056 87,747 Jul 27 05:52 PM Fasolo Peter Exec VP, Chief HR Officer Jul 25 '23 Sale 170.32 20,000 3,406,498 102,696 Jul 27 05:52 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Jun 12 '23 Sale 160.00 12,465 1,994,400 65,934 Jun 14 04:19 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite